David Young - Dec 31, 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
President & CEO, Director, 10%+ Owner
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:39 PM
Previous filing
Oct 3, 2022
Next filing
Feb 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +25.4K +6.76% $0.00 400K Dec 31, 2022 Common Stock 25.4K $0.00 Direct F1
transaction PCSA Restricted Stock Units Award $0 +24K +6% $0.00 424K Jan 1, 2023 Common Stock 24K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. These restricted stock units vest on date of grant.
F2 Each restricted stock units represents a contingent right to receive one share of the issuer's common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death.